BACKGROUND/OBJECTIVES: New methods to measure visceral adipose tissue (VAT) by dual-energy X-ray absorptiometry (DXA) may help discern sex, race and phenotype differences in the role of VAT in cardiometabolic risk. This study was designed (1) to compare relationships of DXA-VAT, anthropometric and body composition variables with cardiometabolic risk factors in obese women;
INTRODUCTION
Accumulation of body fat in the visceral depot is mechanistically related to insulin resistance and the development of type 2 diabetes, hypertension, dyslipidemia and cardiovascular disease. [1] [2] [3] Visceral adipose tissue (VAT) promotes hepatic inflammation, steatosis, insulin resistance and dyslipidemia by releasing free fatty acids, hormones and inflammatory cytokines into the portal circulation that functionally impair insulin sensitivity and action. 4, 5 Although VAT is particularly pathogenic [6] [7] [8] and independently predicts all-cause mortality, 9 mounting evidence suggests that abdominal subcutaneous adipose tissue (SAT) affects the development of obesity-related insulin resistance in certain phenotypes by releasing fatty acids first into the venous circulation and later into the portal vein. 10, 11 With the epidemic of overweight and obesity (body mass index, BMI ⩾ 25) reaching 70% of US adults, 12 there is a need to reliably differentiate and quantify VAT and SAT and discern the differences in the role and function of VAT and SAT by sex, race and metabolically at-risk phenotypes.
Although men have greater VAT accumulation than (premenopausal) women 9, 13, 14 the prevalence of excess intra-abdominal adiposity has increased twofold in US women over the past four decades. 15 This sexual dimorphism in body composition is also apparent in the relationship between intra-abdominal fat and cardiometabolic risk. 16 Racial and ethnic differences are also evident, as South Asian individuals have a greater proportion of VAT compared with Europeans, 17, 18 and European Americans have more VAT than African Americans, even when controlled for total body fat. 19, 20 Despite less VAT, African Americans have greater prevalence of insulin resistance, type 2 diabetes and cardiovascular disease than other population subgroups. [21] [22] [23] Although prior investigations indicate functional roles for both VAT and SAT in racial disparities, 24 more information is needed for further elucidating sex and race differences in the relationships between VAT, SAT and cardiometabolic risk to enable the design of subgroup-specific interventions.
In clinical practice and public health settings, anthropometrics, such as BMI, waist circumference, hip circumference, waist/hip ratio and more recently waist/height ratio, are used as surrogates for intra-abdominal adiposity, as they require less time, expense or technical expertise. Notably, these indicators are predictive of cardiometabolic outcomes in large population groups. 25 However, anthropometric measures are unable to distinguish fat vs lean 1 mass or the amount, type and distribution of adipose tissue. For example, BMI, waist circumference, waist/hip ratio and waist/ height ratio do not discriminate whether a higher value is because of increased total abdominal fat or the proportion of VAT to SAT. Hence, such measures cannot advance science with regard to the particular roles of VAT vs SAT in specific phenotypes such as the 'metabolically healthy' obese or 'metabolically unhealthy' lean. [26] [27] [28] Moreover, manual measures are subjected to high inter-rater variability. 29 Considering these limitations, computed tomography (CT) scan and magnetic resonance imaging (MRI) are the gold standards for quantifying and comparing regional fat amount, type and distribution in research settings. Although these imaging techniques have contributed greatly to understanding metabolic phenotypes, as well as disparities in vulnerability for cardiometabolic disease, 30, 31 their complex and costly technology limits general clinical utility. 32 Thus, there remains the need for more practical, accessible and economical methods to evaluate adiposity and to determine its role in cardiometabolic risk, disease and treatment.
In contrast to CT and MRI, dual-energy X-ray absorptiometry (DXA), originally designed to assess bone mineral density, allows the estimation of whole-body composition from a twodimensional X-ray with low radiation exposure, short scanning time, high precision and low cost. 33 Most often, DXA-estimated intra-abdominal adipose tissue has derived from formulas based on manual manipulation of the abdominal region of interest using anatomical landmarks at the level of the second to fifth lumbar vertebrae. [34] [35] [36] However, such estimation has not distinguished VAT from SAT, and the most reliable estimates derive from nonobese persons. 35, 37, 38 Nevertheless, we previously showed strong correlations between DXA and water-suppressed T1-weighted MRI measures of total and regional body composition, with coefficients of variation less than 2% for DXA-derived adiposity measures. 39 More recently, algorithms in updated versions of the software used on DXA scanners have been developed to segment fat within the android region (~10 cm high from the iliac crest toward the base of the mandible) into VAT and SAT. 40 This DXA-VAT method has been validated against CT in subjects with BMI ranging from 18.5 to 40 kg/m 2 , and it had a coefficient of determination (r 2 ) of 0.959 for women and 0.949 for men. 40 Yet, the relationship between DXA-VAT and cardiometabolic risk factors has not been well established.
This study was designed for the following purposes: first, to test the hypothesis that DXA-VAT is more robustly associated with cardiometabolic risk in obese women of European-American (EA) and African-American (AA) descent compared with other commonly acquired anthropometric and body composition indicators; second, to test the hypothesis that relationships between DXA-derived VAT and established cardiometabolic risk factors differ in obese women by race and, if so, determine thresholds by race that identify the amount of DXA-VAT that elevates risk; and finally, to determine which of the anthropometric, body composition and clinical variables most robustly predict impaired glucose tolerance (IGT) and the metabolic syndrome (MetSx) in obese women.
MATERIALS AND METHODS Subjects
This study is a cross-sectional analysis of DXA-acquired whole-body scans from obese women enrolled in clinical trials conducted at the Vanderbilt Clinical Research Center between 2008 and 2013. Subjects were recruited from local media and electronic advertisements. Scans were included if female subjects were aged ⩾ 21 years, if BMI was ⩾ 30 kg/m 2 and if they were non-smokers. Race was self-identified. To be included in the analysis, subjects had anthropometric (height, weight, waist and hip circumferences), biochemical and clinical data obtained simultaneous with the DXA scan using standardized protocols. Each subject provided written informed consent, and study procedures were approved by the Vanderbilt University Institutional Review Board. Before analysis, subject records were deidentified and stored in a Vanderbilt REDCap database. 41 Anthropometry Physical measures were obtained using standard methods to determine clinical trial eligibility and to acquire baseline data. Height was measured to the nearest 0.1 cm on a wall-mounted stadiometer. Weight was measured to the nearest 0.1 kg on a calibrated digital platform scale without shoes, hats, outer clothing or pocket items. Waist and hip circumferences were measured via flexible measuring tape to the nearest 0.1 cm above the right iliac crest and at the fullest extension of the buttocks, respectively. BMI, waist/hip and waist/height were calculated as ratios.
Dual-energy X-Ray absorptiometry Total and regional body composition was acquired by a certified densitometrist using a Lunar iDXA whole-body scanner (GE Healthcare, Madison, WI, USA) with the enCore 2007 software (version 11.4) . Before each acquisition, the scanner was phantom-calibrated according to the manufacturer's instructions. Duplicate scans after repositioning 12 subjects showed coefficients of variation o 2% for fat and lean total and trunk masses. 39 Scans were imported into an updated version of the software (version 13.6) and reanalyzed using the CoreScan algorithm, which provides automatic segmentation of VAT from total abdominal fat within the android region. VAT mass (g) was automatically transposed into volume (cm 3 ) using a constant correction factor (0.94 g/ml) that is consistent with the density of adipose tissue. 40, 42 Clinical and biochemical cardiometabolic risk factors Blood pressure and heart rate were obtained by research nurses with subjects in a supine resting state using a calibrated sphygmomanometer with a large size cuff. Fasting glucose, insulin, lipid profile (serum total cholesterol, lowdensity lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides (TGs)) and high-sensitivity C-reactive protein (hsCRP) were processed at the Vanderbilt Pathology Laboratory using standard procedures. Serum leptin was processed at the Vanderbilt Diabetes Hormone Core Laboratory. Homeostatic model assessment of insulin resistance (HOMA-IR) was scored using the HOMA2-IR model. 43 Glucose tolerance was measured using a standard 75 g oral glucose tolerance test or a frequently sampled intravenous glucose tolerance test. 44, 45 
Statistical analysis
Data were analyzed using R Statistical Software version 3.0.1 (http://www. r-project.org/). The level of significance was set at α = 0.05. Categorical variables are presented as frequency and percentages, whereas continuous variables are presented as mean ± s.d. Data were checked for normality by visual inspection of histograms and stem and leaf plots. We used Wilcoxon signed-rank tests to assess the significance of inter-group differences.
To determine whether DXA-derived VAT is more robustly associated with cardiometabolic risk factors than anthropometric and other body composition variables, we fitted multiple linear regression models with VAT, anthropometric and body composition variables as independent variables and cardiometabolic risk factors as outcome variables. We then compared the coefficients of determination across the outcome variables while adding race and the interaction between race and the independent variable in the models to identify potential effects of race on these relationships. Next, we calculated areas under the curve (AUC) using binary logistic regression. Regression modeling was performed with VAT unadjusted and adjusted for total fat. To identify variables from the binary regression models that most minimized the sum of the squares of the errors, we performed bootstrapping to resample the individual observations with replacement (N = 200) and LASSO (least absolute shrinkage and selection operator) regression modeling. This process allowed the identification of significant predictors for two separate cardiometabolic outcomes: (1) IGT defined as having fasting glucose ⩾ 100 mg/dl, 2-h glucose between 140 and 199 mg/dl 46 
DXA-VAT and cardiometabolic risk factors
In both groups, DXA-VAT was positively associated with TG, fasting glucose, fasting insulin and HOMA-IR, and negatively associated with HDL-C ( Table 2 ). DXA-VAT was also positively associated with systolic and diastolic blood pressures in EA women, but not in AA women. DXA-VAT was positively associated with hs-CRP in AA women, but not in EA women. We next assessed whether DXA-VAT was more strongly associated with cardiometabolic risk factors compared with the other anthropometric and body composition variables. Incorporating the interaction between DXA-measured VAT predicts impaired glucose tolerance X Bi et al DXA-VAT and race, the strength of the relationships between systolic and diastolic blood pressures to DXA-VAT, BMI, waist circumference, hip circumference, waist/hip ratio and waist/height ratio were similar. However, DXA-VAT explained 10.2% more of the total variance in systolic blood pressure and 11.7% more of the total variance in diastolic blood pressure than the other body composition variables (% body fat, % leg fat, % trunk fat, % android fat and android/gynoid ratio). Waist/hip ratio and android/gynoid ratio explained more of the total variance in HDL-C than DXA-VAT or waist circumference (+13.8, +12.2, +7.5 and +6.9%, respectively). Yet, DXA-VAT explained 24.6% more of the total variance in TG than all other variables. Although waist circumference explained as much of the total variance in fasting insulin as DXA-VAT (r 2 = 21.5 vs 21.7%, respectively), DXA-VAT explained 31.8% more of the total variance in fasting glucose and 25.9% more of the total variance in HOMA-IR than all other variables.
DXA-VAT and IGT
The proportion of EA and AA women with IGT did not differ (29.3 vs 29.2%, Χ 2 (1) = 0.00, P = 0.100). To determine whether DXA-VAT was a more robust predictor of IGT than the other anthropometric and body composition variables, we first compared AUCs and then performed binary logistic regression. DXA-VAT had the highest area under the curve (AUC = 0.766), with AUC values for anthropometric and other body composition variables ranging from 0.467 to 0.702 (Table 3 ). Adjusting the AUC for race (0.767) or incorporating the interaction between DXA-VAT and race (0.760) did not change the significance of the relationship between DXA-VAT and IGT. In determining thresholds where the likelihood of developing IGT was ⩾ 50%, we found that the cutoff points identified DXA-VAT ⩾ 2550 cm 3 in EA women and DXA-VAT ⩾ 2120 cm 3 in AA women (Figure 1 ).
DXA-VAT and MetSx
The proportion of EA and AA women with MetSx also did not differ significantly (39.0 vs 48.1%, Χ 2 (1) = 1.92, P = 0.17). Similar to the findings observed for IGT, DXA-VAT had the highest AUC (0.749) for MetSx, with AUC values for anthropometric and body composition variables ranging from 0.503 to 0.712. Neither adjusting the AUC for race (0.755) nor incorporating the interaction between DXA-VAT and race (0.750) altered the significance of the relationship between DXA-VAT and MetSx. In determining thresholds where the likelihood of developing MetSx was ⩾ 50%, we found the cutoff points identified DXA-VAT ⩾ 1713 cm 3 in EA women and DXA-VAT ⩾ 1320 cm 3 in AA women (Figure 2 ).
Multivariate models for IGT and MetSx
The final analyses were performed to determine the best-fitting multivariate regression models to predict IGT and MetSx in these obese women, using the anthropometric, body composition and cardiometabolic variables that significantly improved the binary regression models. Bootstrapping with LASSO yielded DXA-VAT, systolic blood pressure, fasting insulin and hsCRP as the independent variables that accounted for most of the variability in the outcome of IGT (Table 4a ). DXA-VAT most significantly predicted IGT (P o0.001). Adjusting the model to account for total fat mass, each standard deviation increase in VAT (s.d. = 880 cm 3 ) increases the odds of developing IGT by 4.34-fold. Comparing the residual deviance for the multivariate model with and without race, as well as the interaction between DXA-VAT and race, did not alter the significance of the model (P = 0.92).
With MetSx as the outcome variable (Table 4b) , bootstrapping with LASSO yielded DXA-VAT, HOMA-IR and LDL-C as the independent variables most accounting for the variability in MetSx. Similar to IGT, DXA-VAT most significantly predicted MetSx (P o 0.001). Adjusting the model to account for total fat mass, each standard deviation increase in VAT increases the odds of developing MetSx by 3.84-fold. Again, comparing the residual deviance for the multivariate model with and without race, as well as the interaction between DXA-VAT and race, did not alter the significance of the model (P = 0.33).
DISCUSSION
We previously demonstrated that DXA whole-body scans are as reliable as whole-body continuous MRI for measurement of total fat, total lean, trunk fat and trunk lean masses. 39 The present study extends our prior findings by showing that estimating VAT directly from DXA whole-body scans is a more robust indicator of cardiometabolic risk in women with Class I and Class II obesity of EA and AA descent than other more commonly acquired anthropometric (weight, BMI, waist circumference, waist/hip ratio and waist/height ratio) and DXA-derived (% body fat, % leg fat, % trunk fat, % android fat and android/gynoid ratio) surrogate measures of intra-abdominal adipose tissue. Simultaneous assessment of bivariate relationships with risk factors and comparison of the AUCs between VAT and each anthropometric and body compositon variable using binary logistic regression modeling confirmed the strength of the relationships between DXA-VAT and risk factors in both groups of obese women. Upon evaluating each anthropometric and body compositon biomarker individually, one detectable racial difference was that DXA-VAT correlated with hsCRP levels only in AA women even though their high body mass and elevated serum CRP concentrations suggest the presence of systemic inflammation in all these women. Importantly, animal and human studies confirm that systemic inflammation in obesity is mechanistically linked to insulin resistance and future development of type 2 diabetes and cardiovascular disease, [49] [50] [51] as VAT secretes proinflammatory cytokines such as TNF-α and IL-6 along with chemokines such as macrophage migration inhibitory factor and the CC chemokine receptor 2. 52, 53 Although one study showed higher TNF-α and soluble TNF receptors in EA women, 54 others have reported greater levels of inflammatory biomarkers such as CRP level in African Americans. The higher rates of cardiometabolic disease in AA women suggest greater sensitivity and/or consequences from existing in this state of chronic inflammation. 55 Although overall body fat, trunk fat or leg fat might explain this disparity, the present cohort was well matched in both total fat mass, percent total body fat, percent leg fat, percent trunk fat and percent android fat. Future investigation of other physiological stress factors that may predispose differential response to inflammatory signals may help explain this phenomenon. It is also possible that differences in dietary intakes or physical activities have a role in the relationship between VAT and inflammaton. For example, some long-chain fatty acids (palmitate 56, 57 ) and dietary glycemic load 58, 59 have been shown to induce inflammation and peripheral insulin resistance.
Another detectable racial difference was that DXA-VAT correlated with blood pressure (systolic and diastolic) only in EA women. Neural mechanisms have been suggested as a possible link between excess adiposity and high blood pressure. In prior work, we found that increased skeletal muscle sympathetic nerve activation (measured by recording bursts per minute of sympathetic nerve activity) contributed to obesity-related hypertension. 60 Notably, VAT (measured by CT) correlates better with skeletal muscle sympathetic nerve activity than other body composition measures. Overall, little investigation has been conducted directly assessing racial differences in the association between VAT and blood pressure. One study has reported that the association between the sympathetic nervous system and obesity is less strong in AA women. 61 Yet, findings based on the relationship between waist circumference and systolic blood pressure in women showed conflicting results with regard to race differences. 62, 63 With the high prevalence of hypertension in the AA population, 42 vs 28% in white adults, 64 it may be that mechanisms unrelated to VAT by-products better explain this profound disparity.
Importantly, we further extend current findings by showing that DXA-derived VAT was the strongest predictor of having IGT in both EA and AA women. Now recognized as a condition of prediabetes, IGT currently affects 440 million US adults, elevating the risk for progression to full-blown type 2 diabetes. 65 In fact, the odds of developing IGT was 4.3-fold greater for each standard deviation increase in DXA-VAT, underscoring the physiological role of VAT in the development of impaired insulin action. Having thresholds of DXA-VAT for obese EA and AA women that elucidate at what point the probability of having IGT is at least 50% provides clinically meaningful information, as one-third of Americans who do develop type 2 diabetes remains undiagnosed. 65, 66 Although other studies have reported VAT thresholds, most of the work has been performed in white adults and has focused solely on the construct of the MetSx. Two studies that reported VAT thresholds in African Americans used cross-sectional CT scans to identify VAT. 67, 68 Shedding additional light on the importance of VAT in the ethnic disparities of cardiometabolic risk, the thresholds determined in the present study from DXA-VAT were lower in AA women for both IGT and MetSx. Although our finding for MetSx is in agreement with recent findings from a larger biracial sample where DXA-VAT was assessed similarly using a Hologic brand scanner, 69 our results suggest that in obese women VAT can be highly pathogenic in both EA and AA women. Indeed, we found a 3.8-fold increased likelihood of developing MetSx with each standard deviation increase in VAT.
A considerable strength of this cohort of obese women was that the EA and AA women were not only similar in age but unusually homogeneous in height, waist circumference, total fat mass, as well as percentage total body fat, leg fat, trunk fat, android fat and android/gynoid ratio. Moreover, the proportion of EA and AA women in the cohort was similar, which provided the power to make comparisons and detect inter-group differences. A relative limitation of this study was the cross-sectional design of our analyses, which restricts inference with regard to causality. In addition, the generalizability of the findings is restricted to women with obesity. Although the majority of subjects were normolipidemic, another possible limitation was the inability to review medical records for the use of lipid-lowering or antihypertensive medications, which might influence the biochemical results. Future work is needed with the newer DXA algorithms using prospective and more representative population samples.
In conclusion, the present findings contribute to the accumulating body of evidence that shows that DXA-VAT is a robust indicator of cardiometabolic risk, and more so than other DXA measures such as trunk fat or leg fat. Specifically, this study shows that DXA-VAT predicts having IGT and MetSx in women with Class I and Class II obesity who are of both EA and AA descent. By being able to determine cutoff points in DXA-VAT that identify at what level the risk for having IGT and MetSx elevates substantially in each group, DXA-VAT provides robust information regarding detrimental health consequences of accumulating intraabdominal fat. Compared with other imaging techniques, DXA scanners are widely available, radiation exposure and patient burden is low and cost is modest. With VAT being a fundamentally meaningful measure of cardiometabolic risk and anthropometric DXA-measured VAT predicts impaired glucose tolerance measures being unable to discern fat vs lean mass or differentiate type of fat, recently developed algorithms for assessing VAT by DXA provide clinically useful information to determine cardiometabolic risk and aid in the design of phenotype-specific interventions to reduce risk.
